c-Met / HGFR
Los inhibidores de c-Met/HGFR apuntan al Receptor del Factor de Crecimiento de Hepatocitos (c-Met), una tirosina quinasa involucrada en procesos celulares como el crecimiento, la motilidad y la morfogénesis. La señalización de c-Met está implicada en la progresión del cáncer, la metástasis y la resistencia a terapias. Inhibir c-Met puede interrumpir el crecimiento y la propagación del tumor, lo que hace que estos inhibidores sean valiosos en la investigación del cáncer. En CymitQuimica, ofrecemos inhibidores de c-Met/HGFR para apoyar su investigación en oncología, metástasis y terapias contra el cáncer dirigidas.
Productos de "c-Met / HGFR"
Ordenar por
Hay 91 productos en esta categoría.
Canlitinib
CAS:Canlitinib, a tyrosine kinase inhibitor, holds potential for cancer research.Fórmula:C33H31F2N3O7Pureza:98%Forma y color:SolidPeso molecular:619.61SRI 31215 TFA
CAS:SRI 31215 TFA acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation.Fórmula:C27H34F3N5O3Pureza:98.25% - 99.97%Forma y color:SolidPeso molecular:533.6Ref: TM-T5478
1mg43,00€5mg96,00€10mg135,00€25mg261,00€50mg391,00€100mg557,00€200mg753,00€1mL*10mM (DMSO)101,00€1D228
1D228, a c-Met/TRK inhibitor with antitumor properties, suppresses cyclin D1 to precipitate G0/G1 arrest, thereby inhibiting proliferation and migration ofPureza:98%Forma y color:Odour SolidCEP-40783
CAS:CEP-40783 (RXDX-106) is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).Fórmula:C31H26F2N4O6Pureza:99.45% - 99.64%Forma y color:SolidPeso molecular:588.56Merestinib
CAS:Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.Fórmula:C30H22F2N6O3Pureza:95% - 99.56%Forma y color:SolidPeso molecular:552.53Ref: TM-T3455
1mg49,00€2mg70,00€5mg105,00€10mg144,00€25mg254,00€50mg424,00€100mg605,00€500mg1.264,00€1mL*10mM (DMSO)126,00€PF-04217903
CAS:MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.Fórmula:C19H16N8OPureza:98.41% - 98.55%Forma y color:SolidPeso molecular:372.38Ref: TM-T2676
1mg38,00€2mg49,00€5mg73,00€10mg97,00€25mg172,00€50mg288,00€100mg520,00€1mL*10mM (DMSO)79,00€Afatinib
CAS:Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.Fórmula:C24H25ClFN5O3Pureza:97.56% - 99.9%Forma y color:Off-White SolidPeso molecular:485.94Ref: TM-T21312
5mg35,00€10mg51,00€25mg86,00€50mg115,00€100mg144,00€200mg177,00€500mg300,00€1mL*10mM (DMSO)52,00€PROTAC c-Met degrader-1
CAS:PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.Fórmula:C45H41FN10O5Forma y color:SolidPeso molecular:820.87Onartuzumab
CAS:Onartuzumab (MetMAb) is a humanized monoclonal antibody targeting c-MET, with antitumor effects by blocking HGF and signal transduction.Pureza:97.3%Forma y color:LiquidPeso molecular:146.99 kDaEmibetuzumab
CAS:Emibetuzumab: potent humanized MET antibody, antitumor, inhibits HGF/MET pathways, for advanced prostate cancer research.Pureza:SDS-PAGE:96.2%;SEC-HPLC:98.8%Forma y color:LiquidPeso molecular:143.74 kDaCabozantinib
CAS:Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).Fórmula:C28H24FN3O5Pureza:99.59% - 99.88%Forma y color:SolidPeso molecular:501.51Crizotinib hydrochloride
CAS:Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)Fórmula:C21H23Cl3FN5OPureza:98.73% - 98.87%Forma y color:SolidPeso molecular:486.8Ref: TM-T8399
5mg37,00€10mg52,00€25mg82,00€50mg99,00€100mg138,00€200mg171,00€500mg227,00€1mL*10mM (DMSO)59,00€c-met-IN-1
CAS:c-met-IN-1 is a potent and selective c-Met inhibitor (IC50: 1.1 nM) with antitumor activity.Fórmula:C35H37FN6O5Pureza:98%Forma y color:SolidPeso molecular:640.7Hepln-13
CAS:Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.Fórmula:C17H13BrN2Pureza:97.67%Forma y color:SolidPeso molecular:325.2Ref: TM-T25492
1mg38,00€2mg50,00€5mg85,00€10mg126,00€25mg245,00€50mg364,00€100mg507,00€200mg700,00€1mL*10mM (DMSO)96,00€Crizotinib
CAS:Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinases inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptor.Fórmula:C21H22Cl2FN5OPureza:99% - 99.87%Forma y color:SolidPeso molecular:450.34Narnatumab
CAS:Narnatumab (IMC-RON8) is a humanized antibody targeting the macrophage-stimulating receptor (RON) with antitumor activity, used in advanced malignant solid tumors research.Forma y color:LiquidSYN1143
CAS:SYN1143 (AMG-1) strongly inhibits RON & c-Met with IC50s: 9 & 4 nmol/L.Fórmula:C31H29FN4O5Pureza:98.86%Forma y color:SolidPeso molecular:556.58SU11274
CAS:SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.Fórmula:C28H30ClN5O4SPureza:98.62% - 99.44%Forma y color:Orange PowderPeso molecular:568.09Ref: TM-T6154
1mg47,00€2mg59,00€5mg97,00€10mg150,00€25mg283,00€50mg465,00€100mg688,00€1mL*10mM (DMSO)150,00€SAR125884 hydrochlorid (1116743-46-4(free base))
CAS:SAR125844 is a potent and selective MET kinase inhibitor with a favorable preclinical toxicity profile,(IC50=4.2 nM).Fórmula:C25H23FN8O2S2·HClPureza:97.95%Forma y color:SolidPeso molecular:587Ref: TM-T5677
1mg38,00€5mg60,00€10mg90,00€25mg188,00€50mg279,00€100mg395,00€200mg567,00€1mL*10mM (DMSO)101,00€Glumetinib
CAS:Glumetinib (SCC244) (SCC 244) is a novel potent and selective inhibitor of c-Met kinase (IC50: 0.42 nM).Fórmula:C21H17N9O2SPureza:99.79%Forma y color:SolidPeso molecular:459.48Tyrosine kinase-IN-6
CAS:Tyrosine kinase-IN-6 is a potent inhibitor of RON splice variants, demonstrating significant anticancer and antineoplastic effects [1].Fórmula:C37H31F2N5O5SPureza:98%Forma y color:SolidPeso molecular:695.73SGX-523
CAS:SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.Fórmula:C18H13N7SPureza:100% - 99.49%Forma y color:SolidPeso molecular:359.41Glesatinib
CAS:Glesatinib is an orally active and potent dual inhibitor of MET/SMO.Fórmula:C31H27F2N5O3S2Pureza:98%Forma y color:SolidPeso molecular:619.7Tivantinib
CAS:Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.Fórmula:C23H19N3O2Pureza:98% - 99.41%Forma y color:SolidPeso molecular:369.42S49076
CAS:S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.Fórmula:C22H22N4O4SPureza:95.35% - 97.4%Forma y color:SolidPeso molecular:438.5Ref: TM-T3274
1mg47,00€2mg63,00€5mg84,00€10mg96,00€25mg170,00€50mg305,00€100mg558,00€1mL*10mM (DMSO)92,00€DS-1205
CAS:DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.Fórmula:C41H42FN5O7Pureza:99.28%Forma y color:SolidPeso molecular:735.8X-376
CAS:X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase ALK with potential antineoplastic activity.Fórmula:C25H25Cl2FN6O3Pureza:97.87%Forma y color:SolidPeso molecular:547.41Ref: TM-T3550
1mg35,00€2mg50,00€5mg87,00€10mg119,00€25mg258,00€50mg427,00€100mg582,00€1mL*10mM (DMSO)105,00€Amuvatinib
CAS:Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.Fórmula:C23H21N5O3SPureza:98.48% - 99.54%Forma y color:SolidPeso molecular:447.51KRC-00715
CAS:KRC-00715 is an orally effective inhibitor of c-Met, exhibiting high selectivity with an IC50 of 9.0 nM. This compound specifically inhibits the growth of gastric cancer cell lines with high c-Met expression by inducing G1/S phase block, and reduces the activity of downstream signals, including Akt, Erk, and c-Met itself. In the gastric cancer cell line Hs746T, KRC-00715 demonstrates cytotoxicity with an IC50 of 39 nM and selectively inhibits the proliferation of cell lines that overexpress c-Met. Additionally, KRC-00715 decreases tumor size in Hs746T xenograft mouse models.Fórmula:C25H25F3N8O3Forma y color:SolidPeso molecular:542.51AMG-458
CAS:AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.Fórmula:C30H29N5O5Pureza:99.77% - 99.91%Forma y color:SolidPeso molecular:539.58c-Kit-IN-1
CAS:c-Kit-IN-1 (DCC-2618) is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).Fórmula:C26H21F2N5O3Pureza:98.16% - 98.72%Forma y color:SolidPeso molecular:489.47Ref: TM-T4332
1mg46,00€2mg59,00€5mg87,00€10mg144,00€25mg304,00€50mg542,00€100mg778,00€500mg1.605,00€1mL*10mM (DMSO)94,00€c-Met-IN-18
C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively.Fórmula:C21H15FN4O2Pureza:98%Forma y color:SolidPeso molecular:374.37Umikibart
Umikibart is a humanized IgG4κ antibody targeting HGF, with the corresponding isotype control being HumanIgG4(S228P) kappa, Isotype Control.Forma y color:Odour Liquidc-Met-IN-26
CAS:c-Met-IN-26 (compound 1-170) is an effective inhibitor of c-Met, exhibiting an IC50 of 1.6 nM.Fórmula:C24H19F2N9Forma y color:SolidPeso molecular:471.46BMS-777607
CAS:BMS-777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3.Fórmula:C25H19ClF2N4O4Pureza:98.16% - 98.30%Forma y color:SolidPeso molecular:512.89Ref: TM-T2658
2mg63,00€5mg90,00€10mg142,00€25mg265,00€50mg409,00€100mg727,00€200mg1.091,00€500mg1.636,00€BMS817378
CAS:BMS817378 is a potent and selective inhibitor of MET(IC50 : 1.7 nM).Fórmula:C24H18ClF2N4O7PPureza:100%Forma y color:SolidPeso molecular:578.85Cabozantinib hydrochloride
CAS:Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6Fórmula:C28H25ClFN3O5Pureza:99.97%Forma y color:SolidPeso molecular:537.96Ref: TM-T5164
1mg44,00€2mg55,00€5mg69,00€10mg97,00€25mg169,00€50mg248,00€100mg349,00€200mg568,00€500mg908,00€c-Met-IN-19
c-Met-IN-19 (Compound 21j) is a potent c-Met inhibitor with an IC50 of 1.99 nM and demonstrates cytotoxic effects on various cancer cell lines, including A549,Fórmula:C34H37Cl2FN4O7SPureza:98%Forma y color:SolidPeso molecular:735.65Davutamig
CAS:Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.Pureza:98%Forma y color:LiquidPF-04217903 methanesulfonate
CAS:PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Fórmula:C20H20N8O4SPureza:98%Forma y color:SolidPeso molecular:468.49Golvatinib
CAS:Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factorFórmula:C33H37F2N7O4Pureza:98.24% - ≥95%Forma y color:SolidPeso molecular:633.69MK-8033
CAS:MK-8033 is a new and selective dual ATP competitive c-Met/Ron inhibitor (IC50: 1 nM Wt c-Met).Fórmula:C25H21N5O3SPureza:97.16%Forma y color:SolidPeso molecular:471.53MET/PDGFRA-IN-1
MET/PDGFRA-IN-1 (compound 8c) serves as an inhibitor of MET and PDGFRA proteins, displaying an IC50 of 36 μM against MET.Fórmula:C26H23N7OPureza:98%Forma y color:SolidPeso molecular:449.51Ningetinib
CAS:Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Fórmula:C31H29FN4O5Pureza:99.77% - 99.95%Forma y color:SolidPeso molecular:556.58PHA-665752
CAS:PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.Fórmula:C32H34Cl2N4O4SPureza:97.01% - 99.35%Forma y color:SolidPeso molecular:641.61MGCD-265 analog
CAS:Glesatinib, an oral tyrosine kinase inhibitor, targets c-Met and VEGFR2 with IC50s of 29 nM and 10 nM, may treat cancer.Fórmula:C26H20FN5O2S2Pureza:98.06% - 98.68%Forma y color:SolidPeso molecular:517.6Ref: TM-T6351
2mg35,00€5mg52,00€10mg85,00€25mg164,00€50mg255,00€100mgA consultar1mL*10mM (DMSO)62,00€AMG-208
CAS:AMG-208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1.Fórmula:C22H17N5O2Pureza:98.56%Forma y color:SolidPeso molecular:383.4Tepotinib hydrochloride(1 : x)
CAS:Tepotinib hydrochloride(1 : x) is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14Fórmula:C29H29ClN6O2Pureza:99.81%Forma y color:SolidPeso molecular:529.04Capmatinib 2HCl
CAS:Capmatinib 2HCl (INC-280 2HCl), a c-MET inhibitor, is potent (IC50 = 0.13 nM), highly specific, and induces apoptosis in tumor cells.Fórmula:C23H19Cl2FN6OPureza:98.80%Forma y color:SolidPeso molecular:485.34Ref: TM-T4260
1mg44,00€2mg55,00€5mg70,00€10mg87,00€25mg145,00€50mg258,00€100mg430,00€500mg998,00€1mL*10mM (DMSO)97,00€c-Met inhibitor 1
CAS:c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.Fórmula:C17H14N8SPureza:98.77%Forma y color:SolidPeso molecular:362.41Ref: TM-T10655
1mg85,00€5mg172,00€10mg236,00€25mg398,00€50mg588,00€100mg838,00€1mL*10mM (DMSO)188,00€Capmatinib
CAS:Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Fórmula:C23H17FN6OPureza:99.24%Forma y color:SolidPeso molecular:412.42Capmatinib 2HCl.H2O
CAS:Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Fórmula:C23H21Cl2FN6O2Pureza:99.77%Forma y color:SolidPeso molecular:503.36Ref: TM-T8825
2mg35,00€5mg49,00€10mg69,00€25mg115,00€50mg177,00€100mg283,00€200mg378,00€1mL*10mM (DMSO)56,00€Foretinib
CAS:Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.Fórmula:C34H34F2N4O6Pureza:98.07% - 99.68%Forma y color:SolidPeso molecular:632.65Ref: TM-T3113
2mg39,00€5mg57,00€10mg79,00€25mg133,00€50mg207,00€100mg354,00€500mg848,00€1mL*10mM (DMSO)79,00€Antitumor agent-111
Antitumor Agent-111 (Compound 46), a c-Met kinase inhibitor (IC50 = 46 nM), exhibits both antitumor and antiproliferative effects.Fórmula:C34H29ClF2N6O5Pureza:98%Forma y color:SolidPeso molecular:675.08Pamufetinib
CAS:Pamufetinib (TAS-115) is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase.Fórmula:C27H23FN4O4SPureza:99.39%Forma y color:SolidPeso molecular:518.56Ref: TM-T13108
1mg50,00€5mg106,00€10mg158,00€25mg258,00€50mg379,00€100mg538,00€200mg733,00€1mL*10mM (DMSO)134,00€JNJ-38877618
CAS:JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).Fórmula:C20H12F2N6Pureza:98.84% - 99.52%Forma y color:SolidPeso molecular:374.35Ref: TM-T15617
1mg63,00€2mg89,00€5mg137,00€10mg210,00€25mg424,00€50mg627,00€100mg893,00€500mg1.786,00€1mL*10mM (DMSO)153,00€Rilotumumab
CAS:Rilotumumab (AMG 102) is an HGF-targeting antibody, inhibits HGF/MET signaling, and is used for CRPC and gastric cancer research.Pureza:SDS-PAGE:95% SEC-HPLC:97.51%Forma y color:LiquidPeso molecular:145.2 kDaAltiratinib
CAS:Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,Fórmula:C26H21F3N4O4Pureza:98.98% - 99.39%Forma y color:SolidPeso molecular:510.46BAY-474
CAS:BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probeFórmula:C17H15N5Pureza:98.98%Forma y color:SolidPeso molecular:289.33Ref: TM-T7900
1mg50,00€5mg97,00€10mg170,00€25mg306,00€50mg444,00€100mg620,00€200mg835,00€1mL*10mM (DMSO)114,00€Capmatinib xHCl
CAS:Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50Fórmula:C23H18ClFN6OPureza:98.62% - 99.12%Forma y color:SolidPeso molecular:448.89Telisotuzumab
CAS:Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Pureza:SDS-PAGE:96.4%;SEC-HPLC:98.5%Forma y color:LiquidPeso molecular:145.50 kDaTerevalefim
CAS:Terevalefim (ANG-3777) is an hepatocyte growth factor (HGF) mimetic. Terevalefim selectively activates the c-Met receptor.Fórmula:C9H8N2SPureza:99.53%Forma y color:SolidPeso molecular:176.24Ref: TM-T37596
1mg56,00€5mg119,00€10mg210,00€25mg369,00€50mg537,00€100mg750,00€500mg1.539,00€1mL*10mM (DMSO)119,00€BMS 777607
CAS:BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3. BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.Fórmula:C25H19ClF2N4O4Pureza:100% - 99.89%Forma y color:SolidPeso molecular:512.89Ref: TM-T2699
1mg35,00€5mg79,00€10mg124,00€25mg217,00€50mg359,00€100mg533,00€500mg1.169,00€1mL*10mM (DMSO)92,00€Tyrosine kinase inhibitor
CAS:Tyrosine kinase inhibitor is a tyrosine kinase inhibitor used in combination with fragmenting aromatic nitrogen compounds as antiproliferative agents.Fórmula:C31H31FN6O5Pureza:98%Forma y color:SolidPeso molecular:586.61CSF1R-IN-2
CAS:CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).Fórmula:C20H20FN7O2Pureza:99.29%Forma y color:SolidPeso molecular:409.42C-Met inhibitor D9
CAS:C-Met inhibitor D9 is a c-Met kinase inhibitor.Fórmula:C17H15N3O2Pureza:97%Forma y color:SolidPeso molecular:293.32BMS-794833
CAS:BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.Fórmula:C23H15ClF2N4O3Pureza:98% - 99.69%Forma y color:SolidPeso molecular:468.84Ref: TM-T2419
1mg42,00€2mg52,00€5mg88,00€10mg150,00€25mg296,00€50mg537,00€100mg772,00€1mL*10mM (DMSO)95,00€LMTK3-IN-1
CAS:Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.Fórmula:C18H11F3N4OPureza:100%Forma y color:SoildPeso molecular:356.3SCR-1481B1
CAS:SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitorFórmula:C32H40ClF2N6O13PPureza:98.07%Forma y color:SolidPeso molecular:821.12Ref: TM-T5349
1mg38,00€2mg49,00€5mg79,00€10mg119,00€25mg210,00€50mg350,00€100mg522,00€1mL*10mM (DMSO)107,00€XL092
CAS:XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.Fórmula:C29H25FN4O5Pureza:98.60%Forma y color:SolidPeso molecular:528.53Ensartinib hydrochloride
CAS:Ensartinib hydrochloride (X-396 dihydrochloride) is a potent new-generation ALK inhibitor with high activity against CNS metastases and a broad range of knownFórmula:C26H29Cl4FN6O3Pureza:98.73%Forma y color:SolidPeso molecular:634.36Ref: TM-T22324
1mg66,00€2mg93,00€5mg144,00€10mg227,00€25mg464,00€50mg677,00€100mg938,00€1mL*10mM (DMSO)188,00€JNJ-38877605
CAS:JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.Fórmula:C19H13F2N7Pureza:97.04% - 98.27%Forma y color:SolidPeso molecular:377.35EGFR-IN-8
CAS:EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLCFórmula:C32H23ClF3N7O4Pureza:97.45%Forma y color:SolidPeso molecular:662.02Glesatinib hydrochloride
CAS:Glesatinib hydrochloride is an orally active and potent dual inhibitor of MET/SMO.Fórmula:C31H28ClF2N5O3S2Pureza:98%Forma y color:SolidPeso molecular:656.16NPS-1034
CAS:NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.Fórmula:C31H23F2N5O3Pureza:98.48%Forma y color:SolidPeso molecular:551.54Ningetinib Tosylate
CAS:Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.Fórmula:C38H37FN4O8SPureza:99.93%Forma y color:SolidPeso molecular:728.79PF-04217903 phenolsulfonate
CAS:PF-04217903 phenolsulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Fórmula:C25H22N8O5SPureza:98%Forma y color:SolidPeso molecular:546.56Savolitinib
CAS:Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).Fórmula:C17H15N9Pureza:98.12%Forma y color:SolidPeso molecular:345.36Ref: TM-TQ0210
1mg49,00€2mg64,00€5mg92,00€10mg131,00€25mg210,00€50mg373,00€100mg567,00€1mL*10mM (DMSO)97,00€SAR125844
CAS:SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. (IC50 value of 4.2 nmol/L)Fórmula:C25H23FN8O2S2Pureza:98.39%Forma y color:SolidPeso molecular:550.63Ref: TM-T5467
1mg35,00€5mg79,00€10mg116,00€25mg227,00€50mg364,00€100mg588,00€200mg833,00€1mL*10mM (DMSO)96,00€Afatinib Dimaleate
CAS:Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the EGFR family, with antineoplastic activity.Fórmula:C32H33ClFN5O11Pureza:100% - 98.11%Forma y color:SolidPeso molecular:718.08Ref: TM-T1773
1g467,00€5mg40,00€10mg59,00€25mg87,00€50mg107,00€100mg140,00€200mg188,00€500mg313,00€1mL*10mM (DMSO)66,00€Fosgonimeton acetate
Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).Fórmula:C29H49N4O10PPureza:97.05%Forma y color:SolidPeso molecular:644.69Ref: TM-T39507L
1mg116,00€2mg160,00€5mg238,00€10mg353,00€25mg563,00€50mg758,00€100mg1.017,00€200mg1.359,00€Bozitinib
CAS:Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.Fórmula:C20H15F3N8Pureza:99.16%Forma y color:SolidPeso molecular:424.38Ref: TM-T10585
1mg97,00€5mg216,00€10mg354,00€25mg628,00€50mg905,00€100mg1.264,00€200mg1.700,00€1mL*10mM (DMSO)240,00€c-Met-IN-2
CAS:c-Met-IN-2 is a selective and orally available c-Met inhibitor (IC50: 0.6 nM) with antitumor activity.Fórmula:C24H21FN10OPureza:98%Forma y color:SolidPeso molecular:484.49PROTAC c-Met degrader-3
PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.Fórmula:C51H54N10O7Forma y color:SolidPeso molecular:919.037(Z)-Semaxinib
CAS:(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition forFórmula:C15H14N2OPureza:96.09% - ≥95%Forma y color:SolidPeso molecular:238.28Ref: TM-T2496
1mg57,00€5mg111,00€10mg188,00€25mg331,00€50mg568,00€100mg695,00€200mg948,00€1mL*10mM (DMSO)144,00€MK-2461
CAS:MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with anFórmula:C24H25N5O5SPureza:95.41% - 99.53%Forma y color:SolidPeso molecular:495.55Ref: TM-T6094
1mg52,00€5mg120,00€10mg187,00€25mg363,00€50mg552,00€100mg842,00€200mg1.130,00€1mL*10mM (DMSO)134,00€NVP-BVU972
CAS:NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.Fórmula:C20H16N6Pureza:100% - 98.61%Forma y color:SolidPeso molecular:340.38Ref: TM-T2680
2mg44,00€5mg74,00€10mg97,00€25mg178,00€50mg255,00€100mg359,00€200mg510,00€1mL*10mM (DMSO)84,00€AMG-337
CAS:AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).Fórmula:C23H22FN7O3Pureza:99.26% - 99.9%Forma y color:SolidPeso molecular:463.46Ref: TM-T3209
1mg40,00€2mg52,00€5mg85,00€10mg124,00€25mg197,00€50mg350,00€100mg522,00€200mg748,00€1mL*10mM (DMSO)86,00€MET/PDGFRA-IN-2
MET/PDGFRA-IN-2 (compound 8h) serves as an inhibitor of MET and PDGFRA proteins, promoting apoptosis in cells and impeding the proliferation of MET-positiveFórmula:C29H29N7OPureza:98%Forma y color:SolidPeso molecular:491.59c-Met-IN-17
c-Met-IN-17 is a potent inhibitor of c-Met kinase, demonstrating an IC50 of 0.031 μM, and is applicable in anticancer research. [1]Fórmula:C21H15FN4O2Pureza:98%Forma y color:SolidPeso molecular:374.37
